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Liver failure, whether arising directly from acute liver failure or from decompensated chronic 
liver disease is an increasing problem worldwide and results in many deaths. In the UK only 10% 
of individuals requiring a liver transplant receive one. Thus the need for alternative treatments is 
paramount. A BioArtificial Liver machine could temporarily replace the functions of the liver, buying 
time for the patient’s liver to repair and regenerate. We have designed, implemented and tested a 
clinical-scale BioArtificial Liver machine containing a biomass derived from a hepatoblastoma cell-line 
cultured as three dimensional organoids, using a fluidised bed bioreactor, together with single-use 
bioprocessing equipment, with complete control of nutrient provision with feedback BioXpert recipe 
processes, and yielding good phenotypic liver functions. The methodology has been designed to meet 
specifications for GMP production, required for manufacture of advanced therapy medicinal products 
(ATMPs). In a porcine model of severe liver failure, damage was assured in all animals by surgical 
ischaemia in pigs with human sized livers (1.2–1.6 kg liver weights). The BioArtificial liver (UCLBAL) 
improved important prognostic clinical liver-related parameters, eg, a significant improvement in 
coagulation, reduction in vasopressor requirements, improvement in blood pH and in parameters of 
intracranial pressure (ICP) and oxygenation.
Acute liver failure (ALF) is frequently a catastrophic event as the clinical course is often complicated by 
multi-organ failure with cerebral oedema being the terminal event. Acute liver failure can occur at any age, is 
commonly idiosyncratic with no specific therapy and patients present to hospital critically ill. Approximately 15% 
will recover spontaneously; the remainder fulfil the Kings College transplant criteria and 85% of those are listed 
on an urgent transplant waiting list. Currently in UK more than 20% of patients die on the waiting list. Liver dis-
ease is the only major disease in the UK on the increase, whilst donor organ availability is almost static, thus there 
is a large unmet medical need for an alternative treatment. Since the liver has the capacity to repair and regenerate 
given time, a solution is to provide temporary liver function to “buy time” either for complete recovery or to 
find a suitable donor organ. We have developed a bio-artificial liver machine based on a biomass comprised of 
human-liver derived cells1–4 combined with adsorptive removal of DNA and endotoxin, to be used in an extracor-
poreal circuit, treating the whole plasma fraction of the patient over several hours. The human liver is 1.2–1.6 kg 
containing 1–2 × 1011 hepatocytes; experimental and clinical evidence demonstrates that patients can survive 
even if they have only ~30% of liver function5. The aim of this study was to develop methodology appropriate to 
GMP production for a cell therapy to be delivered on the clinical scale, delivering ~70 billion cells and to test it 
in a severe, non-reversible model of acute liver failure in pigs with liver weights equivalent to those in humans.
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Materials and Methods
Ethics statement. We confirm that all methods were carried out in accordance with relevant guidelines and 
regulations. Title of animal ethics approval: Assessment of the efficacy and safety of a BioArtificial liver machine 
(UCLBAL) on short term survival of pigs with induced liver failure. Animal Ethics Committee, University of 
Cape Town, South Africa Application No.: 014/011, Date received: 20/02/14, Date approved: 06/05/14. We con-
firm that all experimental protocols were approved by a named institutional and/or licensing committee.
Title of human ethics approval: Cultures of human liver cells obtained at surgery: 38/2000 Royal Free local 
research ethics committee. Royal Free Hospital Hampstead NHS Trust, London UK. Date approved 27/02/02.
Statistics were as described in legends to figures, typically Students t test, paired or unpaired as appropriate. 
For technical reasons, some of the in vivo observations were incomplete for all pigs, however, all the available 
data is presented with “n” numbers. The datasets generated during and/or analysed during the current study are 
available from the corresponding author on reasonable request.
Master and Working Cell Banks. Master and Working cell banks (MCB, WCB) of HepG2 cells (ECACC 
Wiltshire) were produced to GMP and fully tested to regulatory standards, including molecular cell line identity, 
such that they can subsequently be used in human cell therapy. 2 ml vials of cells were stored in a GMP cryobank-
ing facility (Fisher Bioservices, Stortford, Hertfordshire), and each preparation was derived from a fresh vial from 
the WCB.
Monolayer culture. A WCB vial of single cells was thawed from liquid Nitrogen storage and used to seed a 
monolayer triple flask (500 cm2, Thermo Scientific Loughborough, Leicestershire) in antibiotic-free culture media 
(MEMalpha, PAA, Pasching, Austria) supplemented with Foetal Calf Serum (10%, PAA, Pasching, Austria) and 
insulin (0.27 IU/mL, Novo Nordisk, Bagsværd, Denmark) and passaged after 4 to 7 days growth. Cells were accli-
matised to supplemented antibiotics during the second passage (penicillin/streptomycin (45 u/ml pen, 45 µg/
ml strep), Thermo Fisher Scientific: Life Technologies, Paisley, Scotland) and fungizone (1.1 µg/mL, Thermo 
Fisher Scientific:Life Technologies, Paisley, Scotland), and at the third passage used to seed 7 x Cell Factories 
(Easy Fill 10, 6320 cm2, Thermo Scientific, Loughborough, Leicestershire). Cells (139 × 106 cells in 1.7 L culture 
media) were used per Cell Factory and grown for 6 days, and then harvested using TrypLE Select (Thermo Fisher 
Scientific:Life Technologies, Paisley, Scotland) dissociation reagent and pelleted at 289rcf (1150 rpm, Thermo 
Scientific Multifuge X3-R; 4-head swing out rotor) (500 mL Corning centrifuge tubes). Resuspended cells were 
counted for viable cell number using an NC-100 Nucleocounter (Chemometec, DK-3450 Allerod, Denmark), and 
then mixed in suspension with alginate for encapsulation.
Alginate preparation. Alginate (80 g) (FMC Ltd) was dispersed and hydrated as a 2% solution using an 
L5M-A Laboratory Mixer (Silverson Ltd, Chesham, Bucks) in 0.15 M NaCl containing HEPES (Thermo Fisher 
Scientific: Life Technologies, Paisley, Scotland), pH7.4.
Cell encapsulation was achieved at a cell concentration of 2 × 106 cells/ml in 1% alginate, using a 
custom-designed multinozzle (8-nozzle) JetcutterTm (GeniaLab GmbH, Germany).
Briefly, 8 L of alginate/cell solution was mixed with a density modifier4,6,7. A cutting disc (60 × 100 µm wires) 
cut the flow of cell mixture into segments that dropped perpendicularly into a stirred polymerisation bath of 
0.204 M CaCl2 solution, with pressurised delivery of the cell mixture to the encapsulator. Calibration at a flow rate 
of 20 ml/min/nozzle was achieved by altering the delivery pressure between 450 and 600mbar. 2.5–3 L spherical 
alginate beads were collected over a period of 30–35 minutes. Polymerisation was continued for a further 5 min-
utes and then cell beads were washed in DMEM four times. Finally beads were collected in MEM-alpha for trans-
fer to a 15 cm ID chamber for fluidisation, enabling culture to performance-competence to provide a UCLBAL 
biocartridge, filled with 3-dimensional cell organoids. For control studies a similar process was used to produce 
equivalent volumes of alginate beads without cell inclusions.
Fluidised bed bioreactor using a Single Use Bioreactor (SUB) Bioprocess Container. To enable 
subsequent clinical use of a cell therapy, GMP processes are essential. All methods described for the prepara-
tion of the biomass were developed to be GMP appropriate, and single use components utilised where possible. 
2.5 L alginate-encapsulated cells (beads/biomass) in the chamber were attached in a perfusion circuit to a stirred 
tank bioreactor with single use bioprocess container (SUB) of 100 L (Hyclone/Thermo Scientific, Cramlington, 
Northumberland) containing 116 L complete culture media3, MEMalpha (PAA), supplemented with insulin 
(0.27 IU/mL, Novo Nordisk) and antibiotics (penicillin/streptomycin (45 u/ml (pen), 45 µg/ml (strep) Thermo 
Fisher Scientific (Life Technologies), Paisley), and fungizone (1.1 µg/mL, GIBCO). Biomass to media ratio was 
1:46. Culture media in the SUB had temperature (37 °C), pH (7.4) and Dissolved Oxygen (DO, 21–35%) meas-
ured via probes (Broadley James, Silsoe, Bedfordshire), and controlled via the ezControl system (Applikon, 
Tewkesbury Gloucestershire) and GMP compliant BioXpert SCADA software.
Media perfusion from the SUB to the base of the chamber (typically 380 mL/min, Watson Marlow peristaltic 
pump) allowed fluidisation of the beads (1.675-fold bed height). A tubing warmer provided additional tem-
perature control to inflowing medium immediately before the chamber (AstothermR Plus 220/220 S, Stihler 
Electronic GmbH, Stuttgart, Germany; Astotube cat #IFT30410 dimensions 6.8mm OD).
Gassing in the SUB was enabled by Mass Flow Controllers inbuilt in the ezControl unit, and entered the dis-
posable bag via an open pipe line, thus minimising frothing whilst enabling rapid response.
Background air supply in the SUB was set at 150–250 mL/min, provided by compressor (Jun-air, OF302). CO2 
and bicarbonate solution were used to maintain pH, oxygen was delivered by a stand-alone oxygen concentrator 
(Newlife Intensity 10, AirSep Corporation, Urmston Manchester); DO in the SUB started at 21% but escalated 
automatically to 35% in response to measurements recorded post-chamber in the perfusion circuit.
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Programmed bespoke ‘recipes’ in BioXpert allowed the dissolved oxygen (DO) setpoint escalation in the SUB, 
as well as feedback loops to control nutrient input and safety measures.
Proliferation of the biomass in the fluidised bed bioreactor (FBB) took 12 days, with regular batch media 
changes in increasing proportions, on days 4/5, 7 and 11. Optimisation runs determined maximum biologi-
cal function, eg protein synthesis by cell spheroids at this time (performance-competence). Daily media sam-
ples for lactate and glucose analysis (Analox GM-7 Micro-Stat analyser), and for synthetic function via AFP 
(alpha-fetoprotein) ELISA were stored at −20C for future analysis. Bead biomass was sampled throughout to 
determine cell density via Nucleocounter (NC-100, Chemometec, Allerod, Denmark), and metabolic viabil-
ity, assessed on a 250 μl sample, via fluorescent staining with 0.0128 mg/mL fluorescein diacetate (FDA: Sigma 
Aldrich, Poole, Dorset) and 0.0256 mg/mL propidium iodide (PI: Sigma Aldrich, Poole, Dorset) vital dyes (final 
concentration), and NIS Elements imaging software.
At harvest, the required total biomass was transported to the site of the animal trial (Animal operating theatre/
ICU, University of Cape Town, Cape Town, South Africa); beads were transferred to 1750 cm2 Corning Roller 
bottles containing oxygenated perfluorodecalin (PFC; F2 Chemicals, Preston Lancashire) and media containing 
HEPES, pH7.4 (GIBCO), at an optimised ratio of oxygen carrier, media and beads8.
Oxygenation of the FBB. Data collected by BioXpert were used to determine the oxygen consumption of 
the fluidised biomass over the process period. Oxygen provision to the biomass in the chamber was determined 
as a function of pressure of inlet oxygen and media flow rate through the chamber.
Validation of cell viability method. Since accurate quantitation of viability in 3D constructs is not a rou-
tine protocol we developed and validated a new assay. The results using the developed analysis protocol were then 
compared to cell counts and protein synthesis and secretion. At least five fields of beads were captured for image 
analysis, typically 100 beads.
To compare living biomass with dead cell beads by image analysis, we initiated cell death deliberately induced 
as negative control in beads by exposure to 50% (w/v) Me2SO for 5, 10 and 15 mins at room temperature, which 
we have established, produces a controllable lethal insult.
Fluorescein diacetate (FDA) identifies viable cells by diesterase conversion to fluorescein, only occurring 
in viable cells, not simply cellular components, and Propidium Iodide (PI) binds to nuclei in membrane per-
meable cells. Alginate encapsulated liver cell spheroids in beads (AELS, 250 μl), washed 2x with 1 ml PBS and 
re-suspended in 500 µl of PBS were stained with 20 µl PI and 10 µl FDA for 90 seconds at ambient temperature, 
washed 2x with 1 ml PBS and transferred to a microscope slide. Images were taken with a Nikon TE200 micro-
scope with a Nikon DS-Fi1c camera (with a 0.67x adapter), DS-U2 PC control unit and NIS Elements software. A 
monochrome set-up was used with a PI excitation filter of 510–560 nm and emission filter of 590 nm and an FDA 
excitation filter of 465–495 nm and emission filter of 515–555 nm.
The quantification method is based on the linearity of fluorescence sum intensity of either PI or FDA to an 
increasing cell number (sum intensity = sum of pixel intensity of all selected pixels (grey scale level from 0–255)). 
To apply the viability formula: “% viability = signal FDA/(signal FDA + signal PI) × 100” an equal number of 
dead and viable cells must provide the same signal (sum intensity). High threshold was set to the maximum of 255 
for both FDA and PI. Final low FDA or PI threshold was taken as the average of 10 images containing between 
40–60 beads per image, including two high cell density samples (22 × 106 and 26 × 106 cells/ml of beads), relevant 
for evaluation of performance competent beads at harvest. No overspill between the green and red filter was 
observed. Available exposure times for NIS-elements suitable for our application were 100 ms 150 ms, 200 ms, 
300 ms, 400 ms, for FDA and 600 ms, 800 ms, 1 and 2 seconds for PI.
FDA set-up (viability > 99%): low threshold was obtained by capturing all pixels with visible cells. Optimum 
exposure time was determined by signal-to-noise ratio (SNR), given by sum intensity of pixels representing cell 
versus pixels without cells.
PI set-up (viability = 0%, same alginate-encapsulated liver cell spheroids in beads (AELS) used for FDA set-up 
were killed with 50% Me2SO): exposure time and low threshold set to obtain same average sum intensity as for 
FDA. This method has shown robust, consistent and equivalent data from viabilities over > 20 runs over more 
than 24 months.
Bioassay for inflammatory response to UCLBAL encapsulated spheroids (biomass). We assessed 12 cytokines 
using FACS analysis (BD™ (Oxford Science Park, Oxford) Cytometric Bead Array (CBA) Human Inflammatory 
Cytokine Kit, Cat No. 551811; and Human Th1/Th2 Cytokine Kit, Cat. No. 550749; Human IL-17A Flex Set, Cat. 
No. 560383; Human IL-8 Flex Set, Cat. No. 558277; and Human GM-CSF Flex Set, Cat. No. 558335) in response 
to biomass exposure. Plasma conditioned with biomass (alginate encapsulated liver cell spheroids - AELS), or 
with empty beads (EABs) was exposed for 24 h to human leukocytes (isolated from volunteer blood with con-
firmed consent), using LPS as a positive control. Peripheral blood mononuclear cell (PBMCs) proliferation was 
estimated by tritiated thymidine incorporation after exposure to biomass-conditioned plasma.
In vitro UCLBAL testing with human plasma. “Performance-competent” biomass (Day 12 FBB harvest) in the 
FBB bioreactor with 2 to 2.4 L biomass was used to treat both bilirubin-spiked (300 µM) fresh frozen normal 
plasma (n = 2, 8 L), as a partial mimic of liver failure in order to demonstrate bilirubin conjugation specifically, 
and liver failure plasma from a patient (n = 1), for 8 hours. 4 L plasma were obtained after apheresis plasma 
exchange in the case of discarded liver failure plasma from a patient who developed acute liver failure due to 
rifampicin, used as anti-TB prophylaxis, and subsequently listed as a candidate for liver transplantation. Clinical 
biochemistry results showed the patient’s plasma to have glucose of 7.1 mmol/L, AFP of 2 kU/L, total bilirubin of 
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84 umol/L, lactate dehydrogenase of 849 U/L, Alkaline phosphatase of 41 U/L, Alanine amino transferase of 91 
U/L and Aspartate aminotransferase of 729 U/L, INR of 5 and Ammonia of >286 umol/L.
Hourly samples were collected to assess bilirubin conjugation, analysed at Great Ormond Street Hospital 
(paediatric VITROS system). Samples were also analysed for glucose consumption, alpha-fetoprotein (AFP) 
production (as an example of biomass-specific protein synthesis, detectable in human plasma), lactate dehy-
drogenase (LDH) activity released into the plasma as a measure of cell damage, Alkaline Phosphatase, Alanine 
Aminotransferase (ALT) and Aspartate Aminotransferase (AST) levels; standard measures of liver function were 
analysed in house (Royal Free Hospital Clinical Biochemistry Department).
In vivo porcine model of acute liver failure treated with BioArtificial liver in the full extracorporeal circuit. 30–
35 kg White-x-Landrace female pigs were used in two groups: the treated group (Cell-BAL, n = 13) contained 
active 3-dimensional (3D) HepG2-cell spheroids in beads (Beads) in a fluidised bed in the UCLBAL chamber; 
control group (Control BAL, n = 15) contained fluidised but empty alginate beads in the chamber, otherwise 
identical. In addition, one pig with liver failure was treated only with plasma in the BAL circuit, and another pig 
was connected to the control circuit but was not subjected to liver failure; these latter two were not included in 
control group data, but served to ensure the system was not of itself detrimental to safety as assessed by physio-
logical stability during anaesthesia.
For preparation of Cell-BAL, the Biomass was separated from PFC transport medium, culture medium 
removed, washed copiously with normal saline and resuspended in heparinised normal porcine plasma obtained 
from the abattoir (1 L) prior to transfer to the fluidised bed chamber in an extracorporeal circuit (Fig. 1 suppl.).
Ischaemic Acute Liver Failure. Anaesthetic regime. Before inducing ischaemic acute liver failure, pigs 
were fasted overnight. They then received continuous anaesthesia throughout, with induction using doses of 
zoletil, butorphanol and medetomidine as premed for tracheal intubation, followed by maintenance with iso-
flurane and/or ketamine, oxygen and nitrous oxide via an endotracheal tube. Fluid management comprised 
0.9% saline at 20 ml/kg/hr and boluses of 0.9% saline to maintain stroke volume variation <15% and a CVP of 
10 mmHg. Glucose was monitored hourly, and 20 ml boluses of 50% glucose in normal saline was given if glucose 
levels fell below 4 mmol/L to maintain normoglycaemia at a glucose level of ≥4 mmol/L.
After anaesthetic induction, intracranial pressure (ICP) probes and brain oxygenation catheters were inserted 
into the brain, with pigs in prone position. Two hours were allowed for physiological brain recovery after the 
surgical craniotomy; thereafter, ICP and brain oxygenation readings were collected as baseline. Thereafter, the 
central venous and arterial catheters were inserted prior to initiation of liver failure by surgical ligation of all 
blood flow to the liver9.
In detail, study animals were moved to the supine position, and remained supine throughout, and had vascu-
lar catheters inserted into the femoral artery and internal jugular vein to monitor arterial and central venous pres-
sure. The liver was exposed via a midline abdominal incision and the ligamentous attachments were divided. The 
portal vein and infrahepatic vena cava were dissected, and the hepatic artery and bile duct ligated and divided. 
The liver was rendered fully ischaemic by ligating the portal vein above a side-to-side portacaval shunt. At com-
pletion of surgery a bolus of heparin (3000 units) was administered.
Two groups of pigs were treated. The control group were connected to the entire extracorporeal circuit, but the 
chamber contained empty alginate beads (EABs). The cell-treated BAL group (Cell-BAL) were connected to an 
identical circuit that contained performance-competent 3-dimensional cell organoids within the alginate beads 
(AELS) in the chamber. Where n numbers are lower than total numbers in each group, the lower number reflects 
technical issues and not selective monitoring.
The UCLBAL circuits were connected to a COBE-Spectra centrifugal plasmapheresis instrument 
(TerumoBCT, Lakewood, Colorado, USA) initially for priming with plasma. The COBE was connected to each 
animal 20 minutes before connection of BAL at 2.47 ± 0.5 h (n = 29, mean ±SD) following surgical ischaemia via 
catheters in the external jugular vein with an inlet blood flow of 90–120 ml/min, and a plasma flow of 30–50 ml/
min into the primary plasma circuit (slow circuit). The plasma priming the BAL circuit was heparinised during 
collection of abattoir blood and the circuit maintained with low dose heparin (1–2unit/ml).
Plasma flow rates were fed into the “fast” circuit fluidising the beads in the UCLBAL chamber at a flow rate of 
350–500 ml/min to achieve a 2-fold fluidised bed height. The UCLBAL circuit was oxygenated. The “slow” circuit 
removed BAL-treated plasma continuously for return to the pig via the plasmapheresis instrument at the same 
flow rate as it was delivered to the BAL, thus ~10% of treated plasma returned and 90% was recirculated at any 
one time. The functional filters were positioned in the slow circuit to ensure removal of cellular debris, DNA and 
endotoxin, and particles >0.6 um prior to return to animal (supplementary Figure 1).
Intraoperative Monitoring. Blood samples were collected (at −1, 2, 3, 4.5, 6, 7.5, and 9 h from ischaemia (t = 0), 
and beyond when necessary) and processed for measurement of liver function tests, blood gases and routine 
haematology (Pathcare Chemical Pathology Service, Cape Town, South Africa). Thromboelastography profiles 
were obtained using both Haemonetics TEG (Harrow) and Rotem (Queens Meadow, Hartlepool, UK) analyses. 
Proteins in pig plasma (human albumin, alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1-fetoprotein, 
fibrinogen and prothrombin) were measured by ELISA; there was no cross reactivity with pig proteins (cap-
ture antibodies: from Dako Ltd (Ely, Cambridgeshire): albumin A0001 10 µg/ml, AGP Q0326 1/1000 stock 
(concentration not specified by supplier), A1at A0012 10 µg/ml; from Abcam plc (Cambridge). AFP ab10071 
1 µg/ml, Fibrinogen ab6666/ab10066/ab106659 1 µg/ml, Prothrombin ab22700 1 µg/ml; Horseradish Peroxidase 
(HRP)-linked antibodies: from Abcam Albumin ab24458–200 0.5 µg/ml, AGP ab34720–10 2.5 µg/ml, AFP 
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ab10072 0.17 µg/ml, A1at ab7635-s 2.5 µg/ml, Fibrinogen ab7539 1 µg/ml /ab106651 1 µg/ml /ab10067 0.7 µg/
ml, and Prothrombin from Fisher Scientific PA1-74092, (Bioscience, Nottingham, UK) LS-C39619-200) 2 µg/ml.
Intracranial pressure was measured with a catheter (Camino, 110–4 g Integra Ltd, Andover) inserted into the 
posterior pole of one hemisphere within the parenchyma at a depth of ~15mm; simultaneously brain oxygenation 
was measured with a monitor and probe (Licox IT2-EU Complete Brain Tunneling Probe Kit /CC1.P1 Oxygen 
and Temperature Probe /VK5.2 Parenteral Probe Guide (Integra Life Sciences, Plainsboro, NJ, USA)10 inserted 
into subcortical tissue. Haemodynamics were assessed using PiCCO technology (Pulse Contour Continuous 
Cardiac Output, Pulsion Medical Systems SE, Germany) via a jugular venous access (Cevox probe, PV2022-32 
monitoring ScVO2 & PiCCO catheter PV2015L20A.) and arterial catheter (Arrow, Uxbridge, Middlesex, UK: 
Central Line Venous Catheter set, BR22853), via the femoral artery. Blood gases were measured with ABL80 Flex 
and ABL8OO Basic blood gas analysers (Radiometer, Crawley, West Sussex, UK).
Control- or Cell-BAL were attached to the test animals for 8 h or until death. Fluid and inotropic support with 
Noradrenaline were used to maintain haemodynamic stability when required, maintaining a mean systolic pres-
sure >70 mmHg and a cerebral perfusion pressure (CPP) > 60 mm Hg as is used clinically.
Results and Discussion
Summary. A clinical sized BioArtificial liver machine (UCLBAL) was prepared and tested in an animal 
model of ischaemic acute liver failure, using GMP-compatible methodology suitable for use in man as a cell 
therapy. A biomass of 7.31 × 1010 ± 1.7 × 1010 viable cells (viability 98.5%, n = 12; variation was not greater than 
3%) was transferred at ambient temperature with oxygenation, from site of production to site of use some 9000 
kilometres distant, with retained viability, indicating this new therapy can be delivered to the bedside of any 
hospital worldwide from a central production facility. There was minimal drop in bead viability (98.4 ± 1.0% to 
93.0 ±3.2%) when Cell-BAL was connected to pigs with liver failure over course of treatment (6–10 hours from 
ischaemia; n = 6, ±SD).
Optimal cell spheroid production within the alginate beads relied on close control of nutrients, gases, temper-
ature and waste product removal in fluidised bed format, achieved with recipe control of fermentation process 
throughout 12 days, using BioXpert software with full CFR pt 11 compliance.
Important parameters of clinical liver failure were improved in the Cell-BAL treated group compared with the 
control (empty bead) BAL group, most notably coagulation, shown and discussed below.
GMP master and working cell banks, and FBB bioprocess. The fully tested GMP working cell bank 
and the initial research cell bank (RCB) performed equally well, despite several changes in protocol to enable 
GMP production. Figure 1a illustrates proliferation. Protein synthesis and production was also maintained 
(WCB: 9291 ± 1526 and RCB: 8611 ± 1797 ng AFP/million cells/day
Scaling up for clinical preparations of the BAL biomass required transition from triple flasks to ~6300 cm2 
cell factories. Hyperflasks (Corning Ltd, 1720 cm2) were compared with 10 layer cell factories from Nunc; the 
latter format was optimal and yielded increased cell number per cm2 (Hyperflasks: 1.81 × 105 cells per cm2; Cell 
Factory: 3.57 × 105 ± 5.2 × 104 cells per cm2, n = 24). Differences in media to plate-surface ratios and available 
oxygenation presumably accounted for improvements of cell factories over hyperflasks. For preparation of 2.5 L 
biomass, 1.56 × 1010 ± 2.4 × 109 total viable cells were harvested from Cell Factories (7 × 6320 cm2 per run; 
n = 24, ±SD) for encapsulation in 1% alginate, as described previously3.
Bead diameter, measured microscopically after encapsulation, was 525.8 ± 95 µm, and after 12 days pro-
liferation in the FBB, 537.0 ± 72 µm (mean ±SD, n = 22). Neither bead diameter, nor bead volume, differed 
significantly during this time, indicating the calcium concentration during production, and culture was not com-
promised with respect to alginate polymerisation, and was conducive to cell spheroid growth. Since epithelial 
cells generally have the adherent phenotype the internal structure of the alginate was sufficient to enable normal 
cell growth and function. Moreover, we have previously demonstrated extracellular matrix synthesis and depo-
sition in the HepG2 cell spheroids within alginate beads, not seen in monolayer culture11. The ~2-fold scale up 
of biomass from our previous study, to human scale required an altered media change regime to achieve optimal 
proliferation over the shortest time. By changing a day 5 media replenishment of 25% to 50% on day 4, day 12 
harvested biomass improved from 2.59 × 107 ± 3.6 × 106 cells/mL (n = 7, ±SD) to 3.27 × 107 ± 4.2 × 106 cells/
mL (n = 14, ±SD), p = 0.0016, representing a 26% improvement in production efficiency. This is an important 
consideration when designing optimum process for later industrial scale up. The average viability of biomass at 
harvest (d12) was 98.3% ± 3%, SD, n = 21 (Fig. 1d).
A combination of media change regime ensured a constant glucose level above 15 mM for cell nutrition, whilst 
lactate levels were maintained below 10 mM, which is an important parameter since high lactate concentrations 
are detrimental to alginate hydrogel stability and can be toxic to cell growth. Amino acid supplementation over a 
20 h period via an automated feed cycle BioXpert recipe maintained nutritional levels.
Validation of cell viability methodology for 3-D structures. Assessing cell viability within the organoids inside 
alginate beads accurately was essential; individual cells could not be analysed by routine viability assays since 
disassociation of organoids to single cells was a destructive process breaking cell-to-cell contacts e.g. junctional 
complexes and desmosomes which created tissue like structures (hence organoids), and were not simply an aggre-
gation of cells.
To assess viable cell-number in 3D organoids we adapted the in situ fluorescence assay of metabolic viabil-
ity, utilising FDA/PI as previously described. Quantification was made via image analysis. To ensure accuracy 
and robustness throughout the given cell density ranges during the growth cycle, validation with respect to the 
method itself, i.e. sum intensity measurements, and correlation with other assays of metabolic function are shown. 
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Cells within the beads proliferated and remained viable during the production process, n = 21, (Fig. 1b–d). 
Comparison of total cell number with viability and cell function are proportional (Fig. 2).
The highest signal-to-noise ratio for FDA and PI was reached with exposure times of 150 ms and one second, 
respectively, with average low threshold for both FDA and PI of 41. PI exposure times of 600 ms and two seconds 
resulted in low signal-to-noise ratios (SNR), either being too short to generate a signal similar to that of FDA 
without including a high percentage of background pixels or too high, meaning that only a few cells (pixels) had 
to be selected. The chosen set up was confirmed with independent samples comparing AELS (same origin) of 
either 99% or 0% viability. There was no significant difference in sum intensity between PI and FDA for samples 
with cell density > 10 000 cells/ml of beads, but FDA intensity was lower in comparison to PI for samples of low 
cell density (3.4 million cells per ml beads, typically seen only on day 1–2 of culture) (Fig. 2a). Viability was also 
compared to non-invasive liver protein secretion (secretion/number cells), cell number and MTT data: value pos-
itive control > value sample 1 > value sample 2 > value sample 3, with the exception that for cell number (positive 
control vs. sample 1, Fig. 2c) and for MTT data (sample 1 to 3) no, or only little distinction between samples was 
detected (thus graphical data not shown). Alpha-fetoprotein secretion was markedly reduced in samples 1–3 up 
to 24 hours after treatment, but upregulated 24 hours later, while fibrinogen and albumin was further reduced or 
remained at a similar level (Fig. 2d–f).
Image analysis is a simple, rapid and economical tool to assess cell-bead viability without the need to disrupt 
either the alginate matrix or cell spheroids. Additionally, there is little scope for variability between operators - an 
important aspect for quality control. When taking TIF images of fluorescent signal, exposure time is recorded 
and an established threshold setting means that intensity is objectively quantified; this contrasts with trypan blue 
exclusion analysis, when a dead/viable cell count is subjective. Simultaneous staining with FDA and PI allows 
calculating the viability of a single bead. Typically our data was collected from at least 100 beads per condition or 
time-point.
Figure 1. (a–d) 1A Comparison of GMP working cell bank (WCB) with research cell bank (RCB): cell 
proliferation. Cell number enumerated by nuclei analysis (Nucleocounter TM) established that proliferation 
was unchanged between WCB, n = 1, and RCB. (UCL HepG2 research bank)–, n = 3 separate experiments, 
n = 5 replicates at each time point), in 6-well plates. (b) Media regime during bioprocess: cell proliferation. 
Cell density in the Fluidised Bed Bioreactor (FBB) was improved with a new media change regime; regime 
1(see also Fig. 1c) gave 2.59 × 107 ± 3.6 × 106 cells/mL biomass at day 12 (n = 7, ± SD); regime 2 gave 
3.27 × 107 ± 4.18 × 106 cells/mL (n = 14, ±SD); p = 0.0016, Student’s t-test. (c). Glucose and lactate monitoring 
during bioprocess. Using regime 2, (n = 14, ± SD); medium was changed on days 4 (50%), 7 (50/60%), 9 (70%) 
and 11 (80%); in this way glucose consumption and lactate production were maintained within safe levels and 
corresponded to replenishment of glucose and removal of lactate. Figure 1d Bead shape, cell proliferation and 
spheroid viability: image analysis. Left: phase images of encapsulated-HepG2 cell beads during bioprocess. 
Magnification x4 (Nikon DS-Fi1c camera and NIS Elements software). Right: visualising live cells, stained with 
fluorescein diacetate (FDA) vital dye, 150 ms exposure time. Average viabilities are shown for each time point; 
n = 21, ± SD. Propidium iodide staining for dead cells was negligible. Scale bar indicates 500 µm.
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Oxygenation of the FBB. Oxygen provision in the FBB process was from two sources. A BioXpert recipe con-
trolled process in the SUB stirred tank reactor from 21–35% via one dissolved oxygen probe (DO1), and then 
from additional oxygenation direct to the biomass containing chamber. Both were controlled from post-chamber 
dissolved oxygen monitoring (DO2), ensuring sufficient oxygenation was afforded to biomass throughout the 
chamber (11.79 +/− 3.5% (mean +/− SD, n = 15), with a non-toxic concentration to the base of the chamber 
from the SUB. Using the oxygen flow rate, transfer across the chamber and difference between DO1 and DO2 
readings, the oxygen consumption was calculated for biomass on day 12, i.e. at performance-competence, to 
be 0.153 ± 0.07 fmol/cell/second, n = 14. This value is greater than observed in our previous study (0.038) and 
from published values of other bioreactors based on different adherent scaffolds at 0.0166 fmol/cell/second)12 or 
hollow fibre cartridge (0.0028 fmol/cell/second)13. This is likely due to improved nutrient and oxygen controlled 
addition in our BAL in the GMP compliant single-use process, with better cell sampling in this design, compared 
with other systems, (hollow fibre and adherent scaffold processes can only achieve direct cell number sampling 
destructively at the end of a process, whereas the FBB enables actual bead sampling on a regular basis). We have 
previously shown no lack of oxygenation across the beads, with proliferation of cells equal throughout the bead 
and no evidence of necrotic centres on histology or electron microscopy14).
Patient safety aspects of the BAL device. The alginate encapsulated biomass was prevented from entering the 
patient in several ways. Firstly the biomass was contained in the fluidising chamber by 200 µm mesh at both 
inflow and outflow; given the size of the beads (~500 µm) intact beads could not escape the chamber. However, 
that may not preclude cell release, if, for example, beads were damaged. Thus two filters were sited downstream of 
the BAL chamber on the patient return side. The first was a depth filter that removed particulates and also bound 
DNA and endotoxin due to its charged nature, and the second downstream of that was a 0.65 µm filter that would 
Figure 2. (a) Quantitation of fluorescent signal for cell spheroid viability assay. Sum intensity of FDA and 
PI signal for alginate encapsulated cell spheroids (AELS) of increasing cell density, indicating that during 
the whole bioprocess production the quantitation of live/dead cells was insensitive to changes in cell density, 
demonstrating equivalency of intensity of PI/FDA output, with the exception of the lowest cell density 
(difference between FDA and PI signal at 3.4 million cells per ml beads, p < 0.05). (b) Viability determined by 
image analysis compared to cell number (c), protein secretion (d–f) Sample 1, 2 and 3, treated with high Me2SO 
to progressively reduce cell viability (5, 10, and 15 minutes in ice-cold 50% Me2SO (w/v)) and a positive control 
(untreated cells) were tested 48 hours after treatment. Viability, cell number and protein secretion per cell 
decreased for samples in the order 1–3. Data was n = 5, ± SD.
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prevent any possible additional cell debris from entering the patient. Important as it is that unwanted components 
are removed, that should not be achieved at the expense of removal of the positive components synthesised by the 
biomass; thus we demonstrated there was no loss of synthesised protein levels after the filter components of the 
BAL using fibrinogen (340 kDa), alpha 1 acid glycoprotein (41–43-kDa) or alpha 1 antitrypsin (52 kDa) as mark-
ers measured over 8 h perfusion. To ensure that the filters did not add any toxic components to the recirculating 
plasma, cells cultured in plasma taken before and after the filters, assayed for metabolic activity (MTT assay 8 
and 24 h after exposure), indicated no differences (data not shown). Particle analysis using NanoSight technology 
(Malvern Ltd, Salisbury, UK) indicated removal of all particles above 0.6 µm. This meets the requirements for 
large volume injectables of <12/ml of >10 um and <2/ml of >25 um15. Finally, since the BAL extracorporeal 
circuit is a secondary process device not attached directly to the patient, the plasma exchange (apheresis) machine 
affords a final patient protection component.
Immunological safety aspects. Cytokine release from the biomass could potentially adversely affect the patient 
were it to return to the patient from the extracorporeal circuit. Cytokine concentrations of IL-1β, IL-6, IL-10, 
TNFα, IL-12p70, IL-2, IL-4, IL-5, IFN-γ, IL-17A and GM-CSF were undetectable in the leukocyte-exposed 
biomass-conditioned plasma; only IL-8 was increased compared with plasma alone or empty beads (Fig. 3a). 
Of the 12 pro and anti-inflammatory cytokines measured, only IL8 was detectable from direct biomass release 
(Fig. 3b), and whilst starting levels in liver failure plasma were high compared with normal plasma, the produc-
tion and release over time was not different in the presence of normal or liver failure plasma. Addressing the 
immune response from a different perspective, proliferation of peripheral blood mononuclear cells (PBMCs), no 
significant increase in cell proliferation was observed when biomass was exposed compared with plasma alone or 
empty alginate beads (Fig. 3c).
Biomass viability and performance in liver failure plasma. Viability dropped by no more than 10% during 
8 hours exposure to the plasma in each in vitro experiment, from 91.3% to 87.2% and 96.8% to 86.6% in the 
bilirubin-spiked plasma experiments, and from 96.3% to 92.0% after exposure to the liver failure plasma (average 
6.2 ± 2%). In addition, at the end of in vivo BAL treatment, in pigs with liver failure, BAL biomass viability was 
still 93.0 ± 3.2%; n = 6, ± SD, adding weight to the lack of cell damage seen in in vitro exposure. The fact that the 
viability of the biomass was not significantly reduced over the course of BAL treatment in vivo, nor in presence 
of human liver failure plasma in vitro, provides good evidence that in patients it would also withstand the toxic 
milieu of circulating liver failure plasma. Analysis of Alkaline Phosphatase (Alk Phos), ALT and AST in the 
treated plasma was unaltered throughout 8 h plasma exposure, indicating lack of cell spheroid damage in presence 
of liver failure plasma. This is important since there are previous reports of liver failure plasma being toxic to cells 
in monolayer culture16 and also in some other BioArtificial liver experimental models17.
Cytochrome P450 activity was demonstrated in biomass (HepG2 3D culture in FBB) and compared with 
primary human hepatocytes. The specific activities were 0.071 in primary human hepatocytes with a range of 
0.022–0.167 (n = 9) pmoles d-luciferase/min/mg protein. In FBB biomass there was 0.041 +/− 0.02 pmoles 
d-luciferase/min/mg protein. This contrasted with the same cells in monolayer culture where specific activities 
were 0.019. (Fig. 2 supplementary)
A functional value of bilirubin conjugation was calculated, based on the total number of cells used and volume 
of plasma treated. About 5 mg conjugated bilirubin is excreted in urine in adults per day (assuming 1 × 1011 total 
liver cells)18. In liver failure plasma, the biomass showed 88.2 mg conjugated/1 × 1011 cells/day.
AFP production and glucose consumption was linear during the 8 h treatment, (Fig. 4b) in normal plasma 
with bilirubin spike and in liver failure plasma, indicating continued function. AFP was used as a marker specific 
to the HepG2 cells and not present in normal human plasma, thus easily differentiating between biomass pro-
duced proteins and those found in normal human plasma. We can readily use AFP to monitor protein synthesis 
and release by the biomass when cultured in human plasma in patients, as a surrogate marker of synthetic func-
tion having previously demonstrated production of five liver specific secreted proteins2.
The bilirubin-spiked plasma experiments had additional glucose supplementation (10 mM).
A slow but non-significant rise in lactate dehydrogenase (LDH) concentration (Fig. 4c) was observed over 
8 hours of incubation with bilirubin-spiked plasma, remaining well within the normal range (range shown as 
dashed horizontal line). As expected, the patient with acute liver failure had very high LDH levels initially, indi-
cating liver cell damage in the patient; however, rate of release during the 8 h treatment was not different to nor-
mal plasma, indicating that the liver failure plasma was not damaging the biomass.
As lactate dehydrogenase is a measure of cell damage we could not have expected to “correct” the values in the 
liver failure plasma as the dead/dying cells would have been in the patient at the time the plasma was collected. 
These results provide additional evidence that the functional capacity of the biomass was not compromised by 
liver failure plasma.
Porcine ischaemic acute liver failure treated with the BioArtificial liver in vivo. The short term cold/ambient chain 
storage solution allowed the biomass to be delivered to the site of the animal trial > 9000 km (6000 miles) from 
site of production.
All animals in both groups had comparable biochemistry and haemodynamic values prior to connection of 
the BAL circuit (supplementary data Tables 1 and 2), with the exception of AST which was higher in the group 
allocated to cell treatment (AST control group = 150 ± 26, n = 16; AST, cell treated group = 311 ± 47, n = 13); 
whilst this is unusual, that it is in the cell-treated group obviates against any bias suggesting improvement in that 
Group is due to them having undergone less liver damage; all 17 other parameters did not differ between the 
groups at this point. Ischaemic surgery was performed blind with respect to BAL treatment.
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Coagulation was assessed by two different methodologies. Prothrombin time and related INR measured by 
routine chemical pathology (Pathcare Pty, South Africa), indicated a significant improvement in the Cell-BAL 
treated group. The control group prothrombin times were 106.1 ± 14 sec (n = 10, ± SEM) and INR of 7.6 ± 1 
(n = 9, ± SEM) at 6–7 h from ischaemia, but these were reduced to 52.2 ± 11 sec (n = 10, ± SEM) and 4.4 ± 1 
(n = 9, ± SEM) in the cell-treated group (and Fig. 3 supplementary). This improvement in coagulation was con-
firmed using Thromboelastography, a serial test of several kinetic parameters associated with blood clotting 
(Fig. 5). The data illustrates initially a worsening in clot kinetics, (e.g. increased R time - time to clot initiation, 
slower time taken to achieve a certain clot strength after initiation - k time and angle), and coagulation index, CI). 
These were followed by improvement once attached to the Cell-BAL back towards normal. CI reflects all of these 
parameters together in a calculated indicator of overall coagulation19 as shown in Fig. 5d. The dramatic improve-
ment of clotting parameters e.g. prothrombin time and INR in Cell-BAL treated group, but not the control group, 
provides good evidence that the normal plasma used to prime the BAL system was not responsible for the efficacy 
since both test and control group were identical except that the control group contained empty alginate beads (no 
cells). Moreover, human proteins including fibrinogen and prothrombin were demonstrable in the pig plasma. 
Figure 3. (a) Cytokine response of peripheral blood human leukocytes to alginate encapsulate liver cell 
spheroids (AELSs) and empty alginate beads (EABs). Plasma conditioned with HepG2-beads (AELS), or empty 
beads (EABs) was exposed for 24 h to human leukocytes using LPS as positive control. Cytokine concentrations 
of IL-1β, IL-6, IL-10, TNFα, IL-12p70, IL-2, IL-4, IL-5, IFN-γ, IL-17A, GM-CSF and IL-8 in the leukocyte-
exposed conditioned plasma were analysed by FACS using a multiplex bead kit (BD™ Cytometric Bead 
Array (CBA) Human Inflammatory Cytokine Kit, Cat No. 551811; and Human Th1/Th2 Cytokine Kit, Cat. 
No. 550749; Human IL-17A Flex Set, Cat. No. 560383; Human IL-8 Flex Set, Cat. No. 558277; and Human 
GM-CSF Flex Set, Cat. No. 558335). (n = 12 in three independent experiments, ±S.D); Student’s T-test, 
***P < 0.001. Only IL-8 was significantly increased in leukocytes exposed to biomass conditioned plasma. 
(b) Biomass production of IL-8 after exposure to liver failure plasma. Normal plasma obtained from healthy 
volunteers; liver failure plasma from two patients, (n = 4 replicates). Starting levels in LFP were higher than 
in normal plasma (patient 1 had 261 pg/ml and patient 2, 197 pg/ml). However, IL-8 was released from BAL 
biomass in both normal (2.24 pg/million cells/h) and liver failure plasma at 3.39 pg/million cells/h after 2 h of 
exposure at similar levels. Levels stabilised by 4 h exposure to < 1 pg/million cells/hour. Thus the environment 
of LFP did not impact on biomass release. (c) PBMC proliferation is not enhanced by empty bead or cell-bead 
conditioned plasma. 1 × 105 PBMCs/well were incubated with normal plasma (Plasma), EAB conditioned 
plasma, AELSs conditioned plasma, normal plasma containing 500 ng/ml lipopolysaccharide (LPS) or RPMI 
medium containing 2 ug/ml Concanavalin A (ConA) for 48 h, and assessed for proliferation. Values are relative 
to the negative control (Plasma alone), ConA showed expected high proliferation, n = 4 replicates, ± SD, 
representative of three separate experiments.
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Since the liver was removed from the circulation, but left in situ, the only source of improved function could be 
the biomass.
A rise in intracranial pressure (ICP), often leading to coma and death in patients, is an important prognostic 
indicator of a fatal outcome in acute liver failure (ALF) in man. There was a variable response between pigs, as 
also occurs in patients, Cell-BAL treated pigs showed either a reduction or stabilisation of ICP that was confirmed 
by appropriate concomitant changes in brain oxygenation measurements; these two parameters were measured 
using independent probes and monitors, providing robust evidence that both parameters were indeed improved 
(Fig. 6). As a rapidly rising intracranial pressure and associated cerebral oedema leads to death, the ability to sta-
bilise and even decrease the intracranial pressure has significant potential clinical benefits in stabilising patients 
with ALF who are awaiting a donor. A rapidly rising intracranial pressure and associated cerebral oedema usually 
precludes liver transplantation.
Metabolic homeostasis is disturbed in liver failure, with a fall in pH and bicarbonate and a rise in anion gap 
and lactate, leading to acidosis, the severity of which is a prognostic sign in ALF in man. Figure 7 illustrates the 
changes in pH over the course of liver failure induction and treatment. In the control group pH continued to 
worsen, whilst in the Cell-BAL treated group pH improved back towards normal.
The need for vasopressor treatment arises in patients with haemodynamic instability; the higher the dose 
required the less able are patients to withstand the rigours of major surgery, such as organ transplant.
Figure 8 shows the comparative requirements for the two groups of pigs requiring noradrenaline to maintain 
mean systolic pressure, indicating a dramatic drop in requirements in the Cell-BAL treated group, compared 
to those in the empty-bead BAL treated group. Since supportive inotropes were used, similar haemodynamic 
stability was recorded in both groups, however the biologically important difference is the lesser requirement for 
inotropic support in the cell BAL-treated group.
Figure 4. (a–c) In vitro testing of biomass exposed to bilirubin-spiked normal human fresh frozen plasma 
(FFP) or patient liver failure plasma over an 8 h period. (a) Biomass conjugation of bilirubin in rifampicin-
induced liver failure plasma. The initial drop in both unconjugated and conjugated seen between −1 and 0 
and 1 hours reflects a dilution effect of plasma with fluid within the hydrogel. From 1 h onwards, conjugated 
bilirubin increases and unconjugated bilirubin falls. (b) AFP production and glucose consumption 
measurements in liver failure plasma; note the linearity over the perfusion time course, an indication of 
continued metabolic viability and functionality. (c) Lactate Dehydrogenase (LD) measurements in two 
experiments with bilirubin-spiked fresh frozen (FFP) plasma and in liver failure plasma. Dashed lines show the 
normal range of LDH between 240–480 units/L.
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All but one animal in each group became anuric (<20 ml/h urine output). All animals developed pulmo-
nary oedema evidenced by increased extravascular lung water (Picco ELWI normal range 3–7mls/kg; average 
in control group over period of ischaemia was 12+/− 2 mls/kg (EVLW 365+/−49) at time of BAL addition and 
12+/−3 at last time point (EVLW 366+/−102) and similarly (as expected in a permanent liver failure model) 
ELWI was 13+/−3 (EVLW 395+/−88) and ELWI 12+/−3 (EVLW 365+/−81) at time of Cell-BAL addition and 
last thermodilution time point respectively.
Furthermore, increasing levels of positive pressure ventilation were required providing further pulmonary 
oedema. Extravascular lung water index is derived from thermo-dilution studies in the Picco performed inter-
mittently, and only possible after the arterial catheterization which occurred during the establishment of liver 
failure surgical model.
This model of acute liver failure in the pigs has strong parallels to ALF in man. It was complicated by 
multi-organ failure as manifested by myocardial failure requiring increasing inotropic support, renal impairment 
with increasing oliguria and eventual anuria leading to fluid overload with pulmonary oedema. Whilst it was not 
possible to assess for peripheral oedema in the skin of pigs, they did develop conjunctival oedema. At the time 
of demise, animals had developed significant ascites. Clinically multi-organ failure is often the cause of death in 
patients, who become increasingly oliguric, eventually anuric and often require renal support usually in the form 
of continuous veno-venous haemodialysis to avoid significant fluid shifts that can exacerbate raised intracranial 
pressure. They also develop adult respiratory distress syndrome and myocardial failure. Other patients develop 
life threatening raised intracranial pressure and cerebral oedema.
We show in Fig. 9, an example of a single pig pair matched for ammonia at the time of addition of BAL. In each 
case, the control as expected showed worsening of parameters of acidosis, whilst with Cell-BAL treatment the 
parameters all improved after BAL addition.
Human proteins were detectable in pig blood samples in the Cell-BAL treated, but not Control BAL (Empty 
bead)-treated pigs (Fig. 10), after BAL addition. Five liver specific secreted proteins were assessed, as well as 
alpha-fetoprotein, a protein not seen in normal blood plasma, but specifically produced by the biomass. AFP 
will be a useful marker of continued biomass function in human trials as it can be assessed by routine chemical 
pathology, whilst biomass production of other human plasma proteins, present in the plasma, is difficult to quan-
tify in the setting of high concentrations of these proteins already and normally present in the patient plasma. The 
Rotem TEG results (Supplementary Figure 4) confirm synthesis of fibrinogen.
Conclusions
The UCLBAL was efficacious in a porcine model of ischaemic acute liver failure using pigs of adequate size to 
reflect the same liver size as expected in man (25.2–34.4 kg pig weights, 0.88–1.71 kg liver weights, n = 25). This 
is indicative of a good chance of success in man. The model chosen was deliberately extremely severe, and irre-
versible, thus removing the possibility of survival as an endpoint. The development of multi-organ failure is the 
common terminal event in patients presenting with acute liver failure and the development of MOF precludes 
liver transplantation. This confirms the severity of the acute liver failure model used and provides the opportunity 
to assess the potential beneficial effect of the BAL on complications that are invariably terminal and preclude 
Figure 5. (a–d) Assessment of clotting function in Cell-BAL treated pigs after induction of liver failure, before 
and after BAL addition. Averaged R time, K time, Angle and Coagulation Index (CI) of Cell-BAL treated pigs 
(± SEM, n = 13); where no error bars are shown, that data point does not have replicates, due to occasional 
technical issues with blood sample analyses. Dashed line indicates baseline normal value. Student’s t-test, 
*p < 0.05.
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Figure 6. Parameters of brain function in four pairs of control and Cell-BAL: animals matched for severity of 
ammonia levels before time of attachment to BAL, as ammonia is a critical precipitant of brain dysfunction. 
BAL addition: vertical dashed line. Control-BAL - ○, dashed; Cell-BAL - ●, solid: (a–d) Intracranial pressure 
(ICP) Examples show the ICP stabilisation enabled by Cell-BAL, (e–h) Brain oxygenation in control and Cell-
BAL: Examples show the increased brain oxygenation enabled by Cell-BAL.
Figure 7. Acidosis in pigs: pH measurement. Control-BAL - ○, dashed trendline, n = 15; cell-BAL - ●, 
solid trend line, n = 13. BAL addition – vertical dashed line. 0.5 ml whole arterial blood was collected into 
heparinised syringes, and 0.2 ml analysed for blood gases including pH using a Radiometer automated analyser.
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transplantation. Moreover, the advantage of the model was that every animal developed severe acute liver failure, 
unlike some chemically induced models where a proportion of animals do not succumb to liver failure20,21 as 
demonstrated in a recent study from Shi et al. using D-galactosamine treated with HiHeps (derived from iPSCs)22.
In our surgical ischaemic model significant liver damage was evident 2 hours after ischaemia was induced, 
so the BAL was attached at ~2.5 h in both control and treated group (2.8 ± 0.5 h from ischaemia, n = 29). The 
degree of severity resulted in survival times of 5–12 h after ischaemia (Control-BAL 7.04 ± 1.9 h, n = 15 (Cell-BAL 
treated 8.21 ± 2.3 h, n = 13; in one control pig rendered ischaemic but not treated with BAL, survival time was 7 h; 
Kaplan Meier survival curve shown in Fig. 5 supplementary), such that the window of opportunity for treatment 
varied from 4–8 h. In man with liver failure it would be appropriate to treat for longer periods, until function of 
the native liver was restored, or in other patients until a donor organ becomes available (the bridge to transplant). 
Consequently, in vitro experiments exposing performance-competent cell beads to liver failure plasma for up 
to 167 hours are ongoing and early indications are encouraging at least up to 24 h. This will be significant in the 
delivery of the treatment in man, increasing the length of potential treatment with a single biocartridge. We have 
previously demonstrated maintained functionality in human liver failure plasma4,23 and the data presented in this 
study confirm those findings. The improvements seen were not identical in all animals, reflecting the fact that the 
main manifestation of ALF differed in different animals. A similar variability occurs in man, thus for example, 
the degree of coagulopathy was variably raised, and in some animals the abnormal parameter was predominantly 
cerebral. Thus, there is no single index of severity to compare between groups; nonetheless it was only in the 
Cell-BAL treated group that improvements were seen.
Particularly striking was the improvement in clotting time, evidenced by two sets of tests (PT/INR, and 
Thromboelastography) in clinical use. Notably, in the control pigs, the PT/INR rose to exceed those levels indi-
cating an urgent need for a transplant in humans (PT > 100 secs; INR > 6), but did not in the animals treated with 
Cell-BAL. These results were assessed by a routine chemical pathology service (Pathcare Pty), similar to that used 
in any hospital setting, and validated by entirely different tests for clotting, assessing four independent parameters 
of clot kinetics, all demonstrating improvements.
Patients with acute liver failure often require high doses of vasopressors to maintain haemodynamic stability; 
this was mimicked in this porcine model, however whilst the control group required escalating does of noradren-
aline, the cell-treated pigs, once established on the BAL, had a reduction or stabilisation of vasopressor require-
ments. In man this would translate to a significant clinical impact given that 75% of patients die from progressive 
multiple organ failure and require increasing inotropic support. Since there is an upper limit of vasopressor 
requirements above which a patient is considered too unstable for transplantation, a device that could prevent this 
futile pharmacological intervention would be considered highly clinically effective. Intracranial pressures were 
also improved and/or stabilised in pig pairs matched for ammonia levels at ischaemia (i.e. before BAL addition), 
and those improvements were mirrored by higher brain oxygenation, indicating better brain function, another 
key clinical parameter in acute liver failure, since raised ICP and associated decreased brain oxygenation and cer-
ebral oedema are common precipitants of death. These results in pigs with human sized livers confirm and extend 
our previous observations8, using a smaller cell mass in smaller pigs which had smaller livers. In the current study, 
the severity of acute liver failure evidenced by prognostic clinical parameters was indeed more severe and had 
a more rapid progression to death, nonetheless clear evidence of effectiveness of the UCLBAL was established.
There are significant differences between the system we have developed and other aspirant technologies. Two 
issues appear paramount; one the cell type providing the biomass, and two, the delivery of function with a wide 
range of bioreactor designs being explored.
With respect to cell type, cells from different species, predominantly human or pig, have been utilised, and 
importantly both primary cells and proliferating cell lines have been employed.
The choice of cells for any BAL is important, balancing availability and practicality with performance and risk. 
Primary pig cells are readily available, however, they have both biological incompatibilities with man and biologi-
cal risks. Pig-human incompatibilities may imperil protein-protein interactions. Further, in a study using porcine 
hepatocytes in a fluidised bed bioreactor in pigs with liver failure, whilst survival time in a D-galactosamine 
Figure 8. Vasopressor requirement: Both Cell-BAL treated (solid line, n = 8) and Control-BAL treated (dashed 
line, n = 6) pigs received noradrenaline infusions into the external jugular vein from 30 min before BAL 
addition. Dose escalation maintained a cerebral perfusion pressure of 60 mmHg.
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model was increased, there were marked perturbations in the serum metabolome, e.g. reductions in some phos-
pholipids in particular phosphatidyl and lysophosphatidyl cholines as well as fatty acids24, molecules intimately 
associated with the stress response. It is also known that primary porcine hepatocytes are prone to loss of function 
and apoptosis in vitro25.
Figure 9. (a–g) Comparison of parameters of severity of acute liver failure in control empty bead BAL (-o-) 
treated pig vs. Cell-BAL treated pig (•), with similar degrees of liver dysfunction prior to connection to the BAL. 
BAL treatment started at 2.5 h. Both pigs had same ammonia levels at connection to the BAL. Control-treated 
pig survived 6 h after liver failure induction, Cell-treated pig survived >12 h after liver failure induction. Vertical 
dashed line signifies time at which BAL was added. (a) pH (b) Lactate. (c) Base and bicarbonate. (d) Anion 
gap. (e) Prothrombin time and INR. (f) ICP change from baseline. Control-BAL (○) exhibited a rapid rise in ICP 
compared with Cell-BAL (●), i.e. Control-BAL 154% change from baseline per hour; Cell-BAL 25% change from 
baseline per hour. (g) Vasopressor requirements: noradrenaline was administered IV at rates required targeting a 
cerebral perfusion pressure (CPP) of 60 mmHg, so the blood pressure was optimised depending on the ICP.
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The failure of a controlled-trial using pig cells in acute liver failure in man26 may well reflect these cell issues. 
Moreover, the use of porcine cells has the risk of transmitting porcine endogenous retroviruses (PERV), and 
whilst to date no patients receiving treatment with porcine cells in BioArtificial liver devices have been infected, 
it is clear from in vitro studies that it is indeed possible27. Gene editing has demonstrated experimentally that 
62 copies of PERV pol can be deleted from PK15 cells28; whether that will be true of all pig cells is yet to be 
demonstrated.
In respect of human cells a lack of availability of primary cells renders this approach non feasible for routine 
clinical practice even though pilot experiments suggest it might be successful. A variety of cell lines have there-
fore been used. We used HepG2 cells and have evidence that in 3-D culture, the functional activity of this cell 
line is equal to primary hepatocytes in situ in many synthetic functions and even drug metabolising functions 
Figure 10. (a–e) Human proteins detected in pig plasma in vivo. Human proteins were produced by cell-BALs 
(-●-) during treatment of ischaemia-induced liver failure pigs, but not in control-BAL treated (-○-) animals; 
the graphs show concentrations that reflect BAL biomass production and any utilisation of those proteins by 
the pig; data are shown as concentrations in whole system, taken from pig blood samples and AUC analysis is also 
shown in legend. Proteins assessed included (a) Albumin (AUC: 136.7 ± 35 total mg produced over treatment by 
cell-BALs;), (b) Alpha-1-Antitrypsin (A1AT; AUC 24.1 ± 5 mg), (c) Alpha-Fetoprotein (AFP; AUC 90.9 ± 22 mg), 
(d) Fibrinogen (AUC 2.6 ± 1 mg), (e) Alpha-1-Acid Glycoprotein (AGP; AUC 4.2 ± 1 mg), (f) Prothrombin (Pro: 
AUC 4.2 ± 1 mg); n = 13, ± SD. Human proteins in Control-BAL treated pigs (-○-) were undetectable.
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are upregulated compared with the poor performance seen in 2D culture, albeit not every function. As we have 
previously shown HepG2 cells do not eliminate ammonia. The urea cycle cannot be completed due lack of argin-
ase 1 and Ornithine carbamoyl transferase29,30. HepG2 cells exhibit the Warburg effect31 of anaerobic glycolysis. 
Alternative proliferating cells include HepaRG cells32,33; these cells, similarly to HepG2 cells, significantly upreg-
ulate their performance in 3D culture34, however, there is controversy as to their robustness on culture in plasma. 
There is some evidence HepaRG cells are damaged by liver failure plasma and to a lesser extent also by normal 
human plasma, thus making them less appropriate for patients with acute liver failure17. This contrasts with our 
experience with HepG2 cells in the UCLBAL bioreactor which function well in normal plasma and maintain 
function and viability in liver failure plasma as we have shown4, (Coward, et al.35, Selden et al.8 and this study). 
Bhattacharya et al.36 have shown that the Warburg effect has been associated with drug resistance leading to a 
survival advantage for cells exhibiting such action. This could be an advantage for a biomass aimed at treating 
acute liver failure, and may go some way to explain why viability remained high in in the biomass throughout the 
treatment with liver failure plasma, both human, in in vitro experiments, and in vivo in the ALF model in pigs.
There are some minor functional differences between HepG2/C3A and HepaRG cells, but the only major dif-
ferences are increased testosterone metabolism and contact inhibition of HepaRG cells. Theoretically, the latter 
might reflect a lower risk should intact cells reach the patient circulation. However, other strategies such as filters 
to exclude cells, particles and DNA re-entering the patient circulation, as are incorporated in our BAL, can obviate 
this risk.
One other consideration should be taken into account; the origin of the cell lines, HepG2 having been isolated 
from a hepatoblastoma of an adolescent male37, whilst HepaRG cells originate from a patient with Hepatitis C38.
Although theoretically human ESC or IPSC derived cells offer potential for generating cells to fill a BAL, 
currently the time and cost of reagents involved in providing cells at the required scale renders this approach 
prohibitive. Furthermore the activity of these cells still does not match that of primary cells39, and reflects an 
immature phenotype.
In respect of bioreactor design, these fall into three broad categories: the hollow fibre-based systems in which 
there is a diffusion barrier placed between the cells and perfusing blood or plasma, and in contrast, flow past sys-
tems where cells are immobilised on a solid matrix eg AMC BAL, and flow through systems such as fluidised bed 
bioreactors. These latter two have no significant diffusion barrier between plasma and cells.
ELAD (Vital Therapies) is a hollow fibre system, where only a < 100,000 Dalton fraction of the plasma is 
treated, and has a diffusion barrier thus reducing effective mass transfer, and a practical complication of pore 
blockage40–43. Moreover, it is impossible to sample cell function directly, rendering quality control difficult, and 
the hollow fibre cartridge is not cryopreservable. Flow past and flow through systems avoid the presence of a 
diffusion barrier. Examples of flow past systems include the AMC bioreactor which uses cells attached to a solid 
surface and has been trialled in man (when charged using pig hepatocytes)44, and more recently using HepaRG 
cells experimentally, but this is still limited by lack of ability to directly sample cell function for quality control and 
lack of cryopreservability. An alternative flow past system, with primary porcine hepatocytes immobilised on the 
external surface of collagen beads, was unsuccessful in human controlled clinical trial45.
Flow through systems, involving either single cells or cell spheroids in a fluidised bed bioreactor potentially 
offer the greatest scope for mass transfer between plasma and biomass7,46,47.
We have previously shown that the alginate encapsulation and cell proliferation enabling generation of 3D 
cell spheroids markedly enhances cell function using an alginate hydrogel without a molecular diffusion barrier 
such as poly-l-lysine. The period of culture to performance-competence allows the generation of endogenous and 
extracellular matrix proteins which contribute to the extracellular milieu of each cell.
A recent paper from Legallais et al.48 has indicated that spheroids made by physical means and then encapsu-
lated in alginate and used in a similar fluidised bed system retain integrity, do not disturb haemodynamic stability 
in normal sheep, and reduce time taken for production. However protein production in their study, e.g. albumin, 
is approximately 200-fold lower that obtained in our UCLBAL system in plasma of pigs with liver failure (Fig. 10 
legend, derived from AUC data), and in culture medium production per cell is one tenth (Legallais et al.49 <70 ng/
million cells/h compared with UCL BAL >800 ng/106 cells/h;). Other designs for fluidised bed bioreactors have 
been tried with spheroids of primary porcine hepatocytes26.
Our BAL design has manufacturing versatility; alginate beads containing cell spheroids could be generated to 
performance competence in individual chambers to be used in one patient or could be processed in bulk to charge 
many BALs. Cell function can be readily sampled on aliquots of alginate beads, enormously enhancing potential 
for quality control required of a clinical cell therapy. Cryopreservation ability offers a pathway to store and dis-
tribute the biomass as and when required for patient use50–56. The financial viability of a BAL as a clinical tool, of 
course remains to be fully established; issues such as costs savings with bulk production, as well as both clinical 
and cost advantages compared to the alternative therapy of liver transplantation are highly relevant considera-
tions. Preliminary costs of goods analysis using research scale costings indicate the feasibility of the UCLBAL. 
Further, this alginate encapsulated cell spheroid/fluidised bed bioreactor system also offers a generic platform 
for three dimensional cell culture that could accommodate any proliferating epithelial cell type including cells 
derived from stem cells, and may have many uses in the era of cell therapy.
Most strikingly of all, the studies reported here have demonstrated efficacy in improving prognostically sig-
nificant parameters of liver failure in a large animal model of severe acute liver failure using a system designed at 
clinical scale.
Applied in the human setting this BioArtificial Liver machine could aid the treatment of patients with acute 
liver failure, allowing time for regeneration of patients’ own liver, obviating the need for transplant. In patients 
with chronic liver failure, suffering periods of decompensation due to bleeding or sepsis it could allow time 
for treatment to reverse the precipitating cause and restore the status quo ante. Patients admitted to inten-
sive care with acute decompensation are at risk of demise in >50% of cases57. Furthermore it could be used 
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peri-transplantation (primary non function or delayed graft function where a newly transplanted organ fails to 
function immediately), or in the setting of liver surgery for metastases requiring resection greater than is usually 
compatible with survival, as well as resection of Hepatocellular carcinoma. In all these circumstances the BAL 
would provide temporary liver support.
Finally, the current trend to use extracorporeal circuits for plasma exchange to stabilise patients awaiting 
transplant indicates that this technology is likely to be readily acceptable for clinical uptake58–60, with the BAL 
providing a bolt-on of biological function to an extracorporeal treatment already in use.
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